Flurbiprofen (Transact, Strepsils Intensive)
Flurbiprofen
Reckitt Benckinser Pharmaceuticals (Pty) Ltd
Registration
- Applicant
- Reckitt Benckinser Pharmaceuticals (Pty) Ltd
- Registrations
- 2
- Schedule source
- SAHPRA documentation
Variants
Regulatory status
Where S1 sits on the scale
Sold by a pharmacist, no doctor's prescription needed.
Schedule 1 medicines are normally sold by a pharmacist, or by a supervised pharmacist intern or assistant, without a doctor's visit; a veterinarian, or a licensed dispensing doctor, dentist or nurse prescriber, may also supply them. A nurse or other non-doctor prescriber may only prescribe the specific substances the Schedule names for that purpose, and may only dispense them if licensed to do so. A child under 12 may only be sold one of these medicines on a prescription, or on a written order that names the purpose and carries a signature the seller recognises.
Schedule S1, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S4; the leaflet's S1 applies to this product.
Who may supply: A pharmacist, or a supervised pharmacist intern or assistant; manufacturers and wholesalers supplying people who may lawfully possess it; a veterinarian, who may prescribe, compound or dispense it; a medical practitioner or dentist, who may prescribe it, and may compound or dispense it only if licensed under section 22C(1)(a); a nurse or other registered non-doctor prescriber, who may prescribe only the Scheduled substances the Schedule identifies for that purpose, and dispense them if licensed to do so; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Flurbiprofen
S4: Flurbiprofen
- when intended for ophthalmic use; (S4)
- except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
Consolidated Schedules 06 July 2026, lines 6390 to 6407
S3: Flurbiprofen
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
- when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i). a maximum of 8,75 milligrams per lozenge; (ii). a maximum treatment period of 3 days; and (iii). a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks. (S0)
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
- when intended for ophthalmic use; (S4)
Consolidated Schedules 06 July 2026, lines 3609 to 3620
S2: Flurbiprofen
- when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days;(S3)
- except when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii)a maximum pack size of 15 lozenges. (S1)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks; (S0)
- except when intended for ophthalmic use. (S4)
Consolidated Schedules 06 July 2026, lines 2014 to 2025
S1: Flurbiprofen
- when in the form of lozenges, indicated for the relief of pain associated with sore throats, subject to: (i) a maximum of 8,75 milligrams per lozenge; (ii) a maximum treatment period of 3 days; and (iii) a maximum pack size of 15 lozenges. (S3)
- except when intended for application to the skin and indicated for the symptomatic relief of localised pain and inflammation, provided that in the case of application by transdermal patch: (i) use is restricted to adults and children 12 years and older; and (ii) the treatment period is limited to a maximum of 4 weeks (S0)
- except when intended for the treatment of post-traumatic conditions, for a maximum period of 5 days; (S2)
- except when intended for ophthalmic use. (S4)
Consolidated Schedules 06 July 2026, lines 465 to 482
Pharmacological class: Ear, nose and throat preparations (class 16)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
2-(3-Fluoro-4-phenylphenyl)propanoic acid
Drag to rotate. Structure from PubChem CID 3394.
SAHPRA documents
Schedule Verification
This medication's schedule (S1) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.